Bank of New York Mellon’s Niagen Bioscience NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $647K | Buy |
202,893
+11,182
| +6% | +$45.4K | ﹤0.01% | 3618 |
|
|
2026
Q1 | $845K | Sell |
191,711
-16,796
| -8% | -$90.7K | ﹤0.01% | 3312 |
|
|
2025
Q4 | $1.33M | Buy |
208,507
+12,063
| +6% | +$83.9K | ﹤0.01% | 3080 |
|
|
2025
Q3 | $1.83M | Buy |
196,444
+11,995
| +7% | +$121K | ﹤0.01% | 2845 |
|
|
2025
Q2 | $2.66M | Buy |
184,449
+11,146
| +6% | +$110K | ﹤0.01% | 2610 |
|
|
2025
Q1 | $1.2M | Sell |
173,303
-3,673
| -2% | -$23.1K | ﹤0.01% | 2958 |
|
|
2024
Q4 | $939K | Buy |
176,976
+21,734
| +14% | +$119K | ﹤0.01% | 3202 |
|
|
2024
Q3 | $567K | Sell |
155,242
-35,200
| -18% | -$111K | ﹤0.01% | 3445 |
|
|
2024
Q2 | $520K | Buy |
190,442
+119,915
| +170% | +$401K | ﹤0.01% | 3567 |
|
|
2024
Q1 | $245K | Sell |
70,527
-15,620
| -18% | -$28.9K | ﹤0.01% | 3868 |
|
|
2023
Q4 | $123K | Sell |
86,147
-239
| -0.3% | -$333 | ﹤0.01% | 4050 |
|
|
2023
Q3 | $126K | Sell |
86,386
-391
| -0.5% | -$611 | ﹤0.01% | 4051 |
|
|
2023
Q2 | $136K | Sell |
86,777
-105
| -0.1% | -$157 | ﹤0.01% | 4051 |
|
|
2023
Q1 | $133K | Hold |
86,882
| – | – | ﹤0.01% | 4022 |
|
|
2022
Q4 | $146K | Sell |
86,882
-116
| -0.1% | -$184 | ﹤0.01% | 4059 |
|
|
2022
Q3 | $107K | Hold |
86,998
| – | – | ﹤0.01% | 4183 |
|
|
2022
Q2 | $145K | Sell |
86,998
-118,408
| -58% | -$232K | ﹤0.01% | 4153 |
|
|
2022
Q1 | $505K | Sell |
205,406
-60
| -0% | -$164 | ﹤0.01% | 3703 |
|
|
2021
Q4 | $767K | Buy |
205,466
+2,503
| +1% | +$13.5K | ﹤0.01% | 3542 |
|
|
2021
Q3 | $1.27M | Buy |
202,963
+21,346
| +12% | +$176K | ﹤0.01% | 3258 |
|
|
2021
Q2 | $1.79M | Buy |
181,617
+5,601
| +3% | +$48.8K | ﹤0.01% | 3063 |
|
|
2021
Q1 | $1.65M | Sell |
176,016
-5,602
| -3% | -$44.4K | ﹤0.01% | 3038 |
|
|
2020
Q4 | $872K | Buy |
181,618
+16,258
| +10% | +$79.3K | ﹤0.01% | 3332 |
|
|
2020
Q3 | $663K | Buy |
165,360
+34,201
| +26% | +$165K | ﹤0.01% | 3345 |
|
|
2020
Q2 | $602K | Sell |
131,159
-3,014
| -2% | -$13.5K | ﹤0.01% | 3382 |
|
|
2020
Q1 | $438K | Buy |
134,173
+1,782
| +1% | +$6.84K | ﹤0.01% | 3444 |
|
|
2019
Q4 | $570K | Buy |
132,391
+6,805
| +5% | +$24.2K | ﹤0.01% | 3530 |
|
|
2019
Q3 | $494K | Sell |
125,586
-1,536
| -1% | -$6.55K | ﹤0.01% | 3542 |
|
|
2019
Q2 | $591K | Sell |
127,122
-240
| -0.2% | -$1.02K | ﹤0.01% | 3522 |
|
|
2019
Q1 | $534K | Sell |
127,362
-1,448
| -1% | -$5.22K | ﹤0.01% | 3517 |
|
|
2018
Q4 | $442K | Buy |
128,810
+24,408
| +23% | +$84.8K | ﹤0.01% | 3548 |
|
|
2018
Q3 | $448K | Buy |
104,402
+3,296
| +3% | +$14.2K | ﹤0.01% | 3695 |
|
|
2018
Q2 | $375K | Buy |
101,106
+77,420
| +327% | +$294K | ﹤0.01% | 3756 |
|
|
2018
Q1 | $99K | Sell |
23,686
-1,793
| -7% | -$9.39K | ﹤0.01% | 4062 |
|
|
2017
Q4 | $150K | Hold |
25,479
| – | – | ﹤0.01% | 4010 |
|
|
2017
Q3 | $110K | Hold |
25,479
| – | – | ﹤0.01% | 3997 |
|
|
2017
Q2 | $97K | Sell |
25,479
-36,351
| -59% | -$115K | ﹤0.01% | 4037 |
|
|
2017
Q1 | $166K | Hold |
61,830
| – | – | ﹤0.01% | 3925 |
|
|
2016
Q4 | $205K | Buy |
61,830
+3,522
| +6% | +$9.57K | ﹤0.01% | 3901 |
|
|
2016
Q3 | $174K | Buy |
58,308
+7
| +0% | +$26 | ﹤0.01% | 3922 |
|
|
2016
Q2 | $241K | Buy |
+58,301
| New | +$276K | ﹤0.01% | 3830 |
|
Other funds holding NAGE
SW
TCM
PAM
SBCM
Bank of New York Mellon's NAGE Position: Q2 2026 in Review
Bank of New York Mellon increased its Niagen Bioscience (NAGE) stake by 5.8% in Q2 2026, buying an estimated $45.4K and bringing the position to 202,893 shares worth $647K. The position accounts for ﹤0.01% of the portfolio, ranked #3618.
Bank of New York Mellon first reported a position in NAGE in Q2 2016 and has held it in 41 quarters since. The position peaked at $2.66M in Q2 2025. 74 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.
- Bank of New York Mellon held 202,893 shares of Niagen Bioscience worth $647K as of Q2 2026.
- Bank of New York Mellon bought 11,182 Niagen Bioscience shares in Q2 2026, an estimated $45.4K.
- Niagen Bioscience made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3618 holding.
- Bank of New York Mellon first reported a position in Niagen Bioscience in Q2 2016 and has held it in 41 quarters since.
- Bank of New York Mellon's Niagen Bioscience position peaked at $2.66M in Q2 2025.
- 74 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.